Coherus Oncology, Inc. (CHRS)

Biological Products, (No Diagnostic Substances)

Latest Price

$1.21

TTM P/E

Normalized P/E

Div Yield

Book Value

0.39

P/B Ratio

3.07

Valuation metrics

EPS: $1.43

Book value / share: $0.50

Formula: √(22.5 × EPS × BVPS)

Graham Number

$4.03

+233% upside

Base FCF: $87M (median of recent 5yr)

Growth: 25%/yr (median YOY, capped at 25%)

Discount rate: 10%

Terminal growth: 3%

Projection horizon: 10 years

DCF Fair Value

$54.69

+4420% upside

EPS: $1.43

Target P/E: 15×

Formula: EPS × P/E

P/E Fair Value

$21.45

+1673% upside

46.1% held by institutions

Institution	Shares	Value	Ownership %	Change	Filing Date
Timothy G. Youngquist 2020 Irrevocable Trust	13.05M	$18.0M	8.45%	+759.8K	2026-06-30
BlackRock, Inc.	12.00M	$16.0M	7.77%	+1.64M	2026-06-30
Vanguard Capital Management LLC	5.95M	$8.0M	3.85%	+496.7K	2026-06-30
Geode Capital Management, LLC	3.69M	$5.0M	2.39%	+564.0K	2026-06-30
Samsara Biocapital, LLC	3.43M	$4.0M	2.22%	--	2026-06-30
Kohlberg Kravis Roberts & Co. L.P.	3.04M	$4.0M	1.97%	--	2026-06-30
State Street Corp	2.38M	$3.0M	1.54%	+56.4K	2026-06-30
Two Sigma Investments, LP	2.26M	$3.0M	1.46%	--	2026-06-30
CM Management, LLC	2.10M	$2.0M	1.36%	--	2026-06-30
C WorldWide Group Holding A/S	1.93M	$2.0M	1.25%	--	2026-06-30